GMAB · Genmab A/S
$31.94
+0.60 (+1.91%)
At close · Aug 14
Market Cap
$19.63B
Shares
614.62M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$31.94
Open$31.31
Day$31.14–31.98
52W close$22.98–35.34
Avg vol 30d2.3M
Short int7.4M · 1.2% float · 4.6d
Short vol85%
Last earningsAug 6, 2026
DataJan 2020–Aug 2026
Up next
Next earnings call
Nov 6, 2026
Est · unconfirmed
· in 12 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Strong
Sentiment
Bullish
Fundamentals
Limited
Quant / Vol
Moderate
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+10%
above
Price vs 50-day avg
+14%
above
RSI (14)
73
overbought
MACD trend
Positive
52-week position
72%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+11%
trailing
6-month return
+9%
trailing
YTD return
+4%
this year
Relative strength
−5%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $28 › 200d $29 — 200d above 50d
Institutional flow
Accumulating
+5% holders QoQ · +49 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.20% of float · ▼ -2.3% MoM · 4.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
290 holders — near 3-yr high, broad support
Squeeze score
48
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
33%
annualized · 1-yr
Max drawdown
−33%
past year
ATR
2.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+10%
Bullish
Price vs 50-day avg
+14%
Bullish
RSI (14)
73
Bearish
MACD trend
Positive
Bullish
52-week position
72%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $28 › 200d $29 — 200d above 50d
Institutional flow
Accumulating
+5% holders QoQ · +49 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.20% of float · ▼ -2.3% MoM · 4.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
290 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $23
Now $32 · 72%
Range high $35
vs 200-day avg +10%
vs 50-day avg +14%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GMAB
this stock
Genmab A/S
|
$19.63B | +3.7% | — | — | 1.2% |
|
ONC
BeOne Medicines Ltd.
|
$513.62B | +14.4% | +22179.2% | 789.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$128.19B | +11.6% | +46.2% | 29.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.72B | +4.1% | +20.8% | 19.9 | 3.3% |
|
ARGX
Argenx SE
|
$52.94B | +1.2% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GMAB | +2.2% | +11.2% | +9.1% | +10.6% | +3.7% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | +1.8% | +6.8% | -4.7% | +6.7% | -10.2% |
Key facts
CIK
1434265
CUSIP
372303206
13F (30d)
290 filings
264 filers
Visit website
Investor relations